Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:JNJ
Previous Symbol
CUSIP47816010
Phone732-524-0400
Debt
Debt-to-Equity Ratio0.46
Current Ratio1.72
Quick Ratio1.40
Price-To-Earnings
Trailing P/E Ratio20.00
Forward P/E Ratio17.89
P/E Growth2.26
Sales & Book Value
Annual Sales$76.45 billion
Price / Sales5.12
Cash Flow$9.6427 per share
Price / Cash15.14
Book Value$24.09 per share
Price / Book6.06
Profitability
EPS (Most Recent Fiscal Year)$7.30
Net Income$1.30 billion
Net Margins1.89%
Return on Equity34.62%
Return on Assets13.90%
Miscellaneous
Employees134,000
Outstanding Shares2,682,900,000
Market Cap$388.16 billion
OptionableOptionable
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Thursday, October 18th. Investors of record on Tuesday, November 27th will be paid a dividend of $0.90 per share on Tuesday, December 11th. This represents a $3.60 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date is Monday, November 26th. View Johnson & Johnson's Dividend History.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday, October, 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. The company earned $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. Johnson & Johnson's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.90 EPS. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson issued an update on its FY18 earnings guidance on Monday, October, 29th. The company provided EPS guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.16.
What price target have analysts set for JNJ?
16 equities research analysts have issued 12-month price objectives for Johnson & Johnson's stock. Their forecasts range from $110.00 to $161.00. On average, they expect Johnson & Johnson's stock price to reach $143.8333 in the next year. This suggests that the stock has a possible downside of 1.5%. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson.
What are Wall Street analysts saying about Johnson & Johnson stock?
Here are some recent quotes from research analysts about Johnson & Johnson stock:
- 1. According to Zacks Investment Research, "J&J’s Pharma segment is performing better than the market in 2018 despite the impact of biosimilars on Remicade sales. Also, the Medical Devices and Consumer units are seeing improving organic growth trends.J&J has raised its full-year organic sales growth outlook thrice this year. Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, we believe that new products in all segments, successful label expansion of cancer drugs like Imbruvica and Darzalex and contribution from recent acquisitions will continue to drive top-line growth. J&J enjoys a robust multi-year pipeline of new drugs and line extensions. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J’s shares have outperformed the industry in the past six months. Headwinds like generics, pricing pressure and soft global market conditions remain." (11/16/2018)
- 2. BTIG Research analysts commented, "Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT. We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report). Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17." (1/24/2018)
Has Johnson & Johnson been receiving favorable news coverage?
News headlines about JNJ stock have trended somewhat positive on Friday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Johnson & Johnson earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN) and Celgene (CELG).
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 58)
- Dr. Paulus A. Stoffels, Vice Chairman of Exec. Committee, Exec. VP & Chief Scientific Officer (Age 56)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 55)
- Mr. Joseph J. Wolk CPA, Exec. VP & CFO
- Mr. Ronald A. Kapusta, Controller & Chief Accounting Officer (Age 59)
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.69%), Bank of New York Mellon Corp (1.26%), Massachusetts Financial Services Co. MA (1.11%), Capital International Investors (0.93%), FMR LLC (0.78%) and Fisher Asset Management LLC (0.42%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Which institutional investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Glenmede Trust Co. NA, Mitsubishi UFJ Trust & Banking Corp, Renaissance Technologies LLC, Fisher Asset Management LLC, American Century Companies Inc., Capital Research Global Investors and Skandinaviska Enskilda Banken AB publ . Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Paulus Stoffels and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Which institutional investors are buying Johnson & Johnson stock?
JNJ stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Matthew Goff Investment Advisor LLC, Independent Franchise Partners LLP, FMR LLC, AQR Capital Management LLC, FIL Ltd, BlackRock Inc. and CIBC World Markets Inc.. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $145.99.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $388.16 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.
What is Johnson & Johnson's official website?
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
